# Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

> **NCT01957644** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 16 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Volasertib

## Key facts

- **NCT ID:** NCT01957644
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-06
- **Primary completion:** 2016-12-16
- **Final completion:** 2016-12-16
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01957644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01957644, "Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01957644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*